In the latest trading session, 0.69 million CRISPR Therapeutics AG (NASDAQ:CRSP) shares changed hands as the company’s beta touched 1.63. With the company’s most recent per share price at $52.55 changed hands at -$2.6 or -4.71% at last look, the market valuation stands at $4.49B. CRSP’s current price is a discount, trading about -73.36% off its 52-week high of $91.10. The share price had its 52-week low at $43.42, which suggests the last value was 17.37% up since then. When we look at CRISPR Therapeutics AG’s average trading volume, we note the 10-day average is 1.8 million shares, with the 3-month average coming to 1.37 million.
Analysts gave the CRISPR Therapeutics AG (CRSP) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.17. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended CRSP as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. CRISPR Therapeutics AG’s EPS for the current quarter is expected to be -1.21.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CRISPR Therapeutics AG (NASDAQ:CRSP) trade information
Instantly CRSP was in red as seen in intraday trades today. With action 4.27%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -16.05%, with the 5-day performance at 4.27% in the green. However, in the 30-day time frame, CRISPR Therapeutics AG (NASDAQ:CRSP) is 3.53% up. Looking at the short shares, we see there were 19.39 million shares sold at short interest cover period of 11.99 days.
The consensus price target for the stock as assigned by Wall Street analysts is 89.5, meaning bulls need an upside of 41.28% from its recent market value. According to analyst projections, CRSP’s forecast low is 52 with 180 as the target high. To hit the forecast high, the stock’s price needs a -242.53% plunge from its current level, while the stock would need to tank 1.05% for it to hit the projected low.
CRISPR Therapeutics AG (CRSP) estimates and forecasts
Data shows that the CRISPR Therapeutics AG share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -9.82% over the past 6 months, a -164.95% in annual growth rate that is considerably lower than the industry average of 17.60%. Year-over-year growth is forecast to reach -96.12% down from the last financial year.
Consensus estimates given by 20 financial analysts project the company’s revenue in the current quarter to hit an average of 7.38M. 11 analysts are of the opinion that CRISPR Therapeutics AG’s revenue for the current quarter will be 10.54M. The company’s revenue for the corresponding quarters a year ago was 201.21M and 504k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -96.33%. The estimates for the next quarter sales put growth at 1,992.03%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 10.83%. The 2024 estimates are for CRISPR Therapeutics AG earnings to decrease by -165.41%, but the outlook for the next 5-year period is at -3.70% per year.
CRSP Dividends
CRISPR Therapeutics AG is expected to release its next quarterly earnings report in January.
CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.71% of CRISPR Therapeutics AG shares while 72.83% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 74.10%. There are 72.83% institutions holding the CRISPR Therapeutics AG stock share, with CAPITAL INTERNATIONAL INVESTORS the top institutional holder. As of 2024-06-30, the company held 9.6159% of the shares, roughly 7.87 million CRSP shares worth $424.8 million.
ARK INVESTMENT MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 9.5098% or 7.78 million shares worth $420.12 million as of 2024-06-30.
Among Mutual Funds, the top two as of Oct 31, 2024 were ARK ETF Tr-ARK Innovation ETF and New Perspective Fund Inc. With 5.42 shares estimated at $283.92 million under it, the former controlled 6.34% of total outstanding shares. On the other hand, New Perspective Fund Inc held about 5.50% of the shares, roughly 4.69 shares worth around $245.92 million.
